Depression and its treatment in cardiac patients

Related Experiment Video

Updated: Nov 8, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

F Fernandez1

  • 1Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas.

Texas Heart Institute Journal
|January 1, 1993
PubMed

Insights

Untreated depression in cardiac patients negatively impacts outcomes. A systematic approach to diagnosing depression and understanding psychotropic medication effects is crucial for effective cardiovascular patient care.

Area of Science:

  • Cardiology
  • Psychiatry
  • Clinical Pharmacology

Background:

  • Depression is a common comorbidity in cardiovascular disease patients.
  • Inadequate treatment or inappropriate psychotropic medication can worsen patient cardiac conditions and overall health.
  • A structured diagnostic process is essential for accurate depression assessment in this population.

Purpose of the Study:

  • To review standard and alternative pharmacotherapies for depression in patients with cardiovascular disease.
  • To emphasize the importance of a systematic approach for differential diagnosis of depression in cardiac patients.
  • To guide physicians in selecting appropriate psychopharmacologic treatments considering cardiac status and drug properties.

Main Methods:

  • Review of current literature on depression management in cardiovascular disease.
  • Analysis of diagnostic criteria for depression.
  • Evaluation of pharmacologic properties and cardiovascular effects of psychotropic agents.

Main Results:

  • Depression diagnosis requires differentiating it from other psychiatric disorders.
  • Knowledge of psychotropic drug properties and cardiovascular effects is vital for safe and effective treatment.
  • A systematic approach ensures correct treatment strategies tailored to individual patient needs.

Conclusions:

  • Effective management of depression in cardiac patients necessitates careful diagnosis and tailored pharmacotherapy.
  • Physicians must possess comprehensive knowledge of psychotropic medications and their cardiovascular implications.
  • Systematic evaluation and appropriate psychopharmacologic selection are key to improving outcomes for cardiac patients with depression.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...